60 related articles for article (PubMed ID: 12447952)
1. Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.
Stabler SN; Ensom MH
Can J Hosp Pharm; 2011 May; 64(3):182-91. PubMed ID: 22479053
[TBL] [Abstract][Full Text] [Related]
2.
Altamirano-Beltrán A; Chiara-Chilet C; López JW; Pons MJ; Maquera-Afaray J
Germs; 2023 Mar; 13(1):72-79. PubMed ID: 38023950
[TBL] [Abstract][Full Text] [Related]
3. Unmasking the Silent Threat: Cefepime-Induced Thrombocytopenia.
Chowdhury T; Karki S; Anitha Rajeev P; Sajeev AT; Aryal B; Bellamkonda A; Basnet P; Panigrahi K
Cureus; 2023 Oct; 15(10):e46518. PubMed ID: 37927729
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
Edwards SJ; Clarke MJ; Wordsworth S; Welton NJ
Curr Med Res Opin; 2009 Jan; 25(1):251-61. PubMed ID: 19210156
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cefepime: a systematic review and meta-analysis.
Yahav D; Paul M; Fraser A; Sarid N; Leibovici L
Lancet Infect Dis; 2007 May; 7(5):338-48. PubMed ID: 17448937
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.
Takigawa M; Tanaka H; Suwa J; Obara T; Maeda Y; Sato M; Shimazaki Y; Onoda T; Ishigami A; Ishii T
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109716
[No Abstract] [Full Text] [Related]
7. Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic.
Toriumi R; Yaegashi H; Kadomoto S; Iwamoto H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Cancer Sci; 2023 Jan; 114(1):201-210. PubMed ID: 35838191
[TBL] [Abstract][Full Text] [Related]
8. Bacterial Translocation in Gastrointestinal Cancers and Cancer Treatment.
Kouzu K; Tsujimoto H; Kishi Y; Ueno H; Shinomiya N
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203589
[TBL] [Abstract][Full Text] [Related]
9. Detection of bacteria in blood circulation in patients receiving cancer chemotherapy.
Ota A; Morita S; Matsuoka A; Shimokata T; Maeda O; Mitsuma A; Yagi T; Asahara T; Ando Y
Int J Clin Oncol; 2020 Jan; 25(1):210-215. PubMed ID: 31407169
[TBL] [Abstract][Full Text] [Related]
10. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
11. Meropenem Assessment before and after Implementation of a Small-Dose, Short-Interval Standard Dosing Regimen.
Chow I; Mabasa V; Chan C
Can J Hosp Pharm; 2018; 71(1):14-21. PubMed ID: 29531393
[TBL] [Abstract][Full Text] [Related]
12. The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis.
Andreatos N; Flokas ME; Apostolopoulou A; Alevizakos M; Mylonakis E
Open Forum Infect Dis; 2017; 4(3):ofx113. PubMed ID: 28761897
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).
Averbuch D; Cordonnier C; Livermore DM; Mikulska M; Orasch C; Viscoli C; Gyssens IC; Kern WV; Klyasova G; Marchetti O; Engelhard D; Akova M;
Haematologica; 2013 Dec; 98(12):1836-47. PubMed ID: 24323984
[TBL] [Abstract][Full Text] [Related]
14. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.
Averbuch D; Orasch C; Cordonnier C; Livermore DM; Mikulska M; Viscoli C; Gyssens IC; Kern WV; Klyasova G; Marchetti O; Engelhard D; Akova M;
Haematologica; 2013 Dec; 98(12):1826-35. PubMed ID: 24323983
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.
Paul M; Dickstein Y; Schlesinger A; Grozinsky-Glasberg S; Soares-Weiser K; Leibovici L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD003038. PubMed ID: 23813455
[TBL] [Abstract][Full Text] [Related]
16. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Paul M; Yahav D; Bivas A; Fraser A; Leibovici L
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005197. PubMed ID: 21069685
[TBL] [Abstract][Full Text] [Related]
17. Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials.
Edwards SJ; Clarke MJ; Wordsworth S; Emmas CE
Eur J Clin Microbiol Infect Dis; 2008 Jul; 27(7):531-43. PubMed ID: 18373108
[TBL] [Abstract][Full Text] [Related]
18. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
[TBL] [Abstract][Full Text] [Related]
19. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
